Skip to content

Investor Relations

Corporate Profile

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and product excellence.

Investor Resources

Aug 14, 2020

Upcoming Events

 

Annual General and Special Meeting of Shareholders

Oct 29, 2020, 10:00 AM PST

Location 

Virtually via LUMI meeting platform: https://web.lumiagm.com/291143138

Read more

Stock Information

OPERATING ASSETS

41.3%-owned joint venture, Pure Sunfarms (PSF), is located in Delta, British Columbia. Its fully operational 1.1 million square foot facility is producing high quality, affordably priced products. The state-of-the-art hybrid greenhouse is one of the largest, lowest operating cost cannabis cultivation facilities in the world. PSF successfully launched its line of branded products into Ontario, British Columbia and Alberta and continues to focus on expanding its sales territories and brand presence as well as developing value-added oils and Cannabis 2.0 products.

Verdélite, Emerald’s wholly-owned 88,000 square feet indoor grow facility in Saint-Eustache, QC, is a Licensed Producer and has a Standard Processing license, allowing it to not only cultivate and sell cannabis flowers but package, extract, manufacture, synthesize, test and sell next-generation cannabis products. Verdélite is now licensed to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers. 

Emerald’s Richmond operation has been designed for health and wellness-oriented organic cannabis cultivation and consists of a 78,000 sq. ft. purpose-built greenhouse facility. The facility received its organic certification and is now in full production while a second 78,000 sq. ft greenhouse is under construction. The organically grown products produced at this facility will play an integral role in the expansion of Emerald’s product line. They will be particularly focused on serving adult-use and medical consumers seeking health and wellness benefits.

Victoria, Emerald’s wholly-owned 10,000 square foot facility in Victoria, BC, includes a 2000 square foot indoor grow and a 6000 square foot packaging and extraction operation. Victoria is Emerald’s Medicinal Cannabis hub, where customer relations, packaging and distribution take place. Victoria’s R&D lab is focused on plant genetics, breeding and next generation cannabis products development.

Avalite, Emerald’s wholly-owned analytical testing laboratory, is a Licensed Dealer and authorized to import and export cannabis and cannabis oils for R&D, prepare any manipulation, formulation, dosage form, strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances – expanding possible research and product innovation opportunities.

Emerald Health Naturals, Emerald’s 51/49 joint venture with Emerald Health Bioceuticals has exclusive Canadian distribution rights of the award-winning Endo product line (PhytoCann® Complex) of non-cannabis endocannabinoid-supporting products that can be sold through natural health product channels. The unique branding opportunity introduce consumers to the benefits of endocannabinoid-supporting products with the Emerald name.

STRATEGIC PARTNERSHIPS

Emerald entered into a multi-year agreement with Valens GroWorks Corp. to contract cannabis extraction and white-label product development services. Under the Agreement, Emerald will supply Valens with a minimum of 10,000 kg of cannabis and hemp biomass annually for processing into premium quality resins and distillates using Valens’ extraction and processing methods. Valens will also provide white label services including formulation, mixing and filling for product formats such as vaporizers, softgels and tinctures.

Emerald Health Biotechnology Espana is a cannabis-industry-leading research organization which Emerald has contracted to elucidate the mechanism of action of proprietary formulations and dosage forms for product development. This collaboration can strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery and dosage.

REBECCA WONG

Vice President, Quality and Regulatory Affairs

[3:36 PM] Azaria Botta

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

JENN HEPBURN

Chief Financial Officer

Ms. Hepburn brings over a decade of experience in accounting and finance to the team at Emerald Health Therapeutics. She is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held Controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

AVTAR DHILLON

Executive Chairman

Dr. Dhillon is a life sciences entrepreneur with more than 35 years of experience. As a founder/co-founder or lead investor in dozens of life science companies, he has raised more than $1B in public and private financings. He is currently the Chairman, CEO and President of Emerald Health Sciences, a holding company with a portfolio broadly focused on the development of pharmaceutical, botanical, and nutraceutical products, including a controlling position in Emerald Health Therapeutics. As President and CEO of Inovio Pharmaceuticals, Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.). Dr. Dhillon now serves as an active board member and chairman for multiple life science and investment companies, and was previously Chairman of the Cannabis Canada Council. Prior to his business career, Dr. Dhillon practiced family medicine. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.

RIAZ BANDALI

President & Cheif Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and, Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.

RIAZ BANDALI 

President & Chief Executive Officer 

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and, Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.s